Lupin gets USFDA nod for Doxercalciferol Injection

Pharma major Lupin announced receiving the approval for its Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials from USFDA. 

The injection 4 mcg/2 mL (2 mcg/mL) is a generic version of Genzyme’s Hectorol Injection. It is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.

The IQVIA MAT September 2018 indicates that Doxercalciferol Injection 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials had annual sales of approximately US$133 million in the US market.

Lupin develops and delivers a wide range of branded and generic formulations, biotechnology products and APIs globally. The company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

On Monday, the shares of the company opened at Rs. 851 per share against its Friday’s close of Rs 849.40 on the BSE. The intraday high was Rs. 861 and intraday low was Rs. 843 per share on the BSE. Its 52-week high was Rs. 1,070 and 52-week low was Rs. 723.55 per share. The shares of Lupin closed at Rs 853.45, up 0.48 per cent. Meanwhile, the BSE Sensex closed at 34,950, down by 0.17 per cent.